Literature DB >> 11573848

Olanzapine-induced rhabdomyolysis.

C J Rosebraugh1, D A Flockhart, S U Yasuda, R L Woosley.   

Abstract

OBJECTIVE: To report a possible case of olanzapine-induced rhabdomyolysis with concomitant lithium-induced pseudo-infarction electrocardiogram changes. CASE
SUMMARY: A 13-year-old white boy was admitted to the hospital with profound weakness and electrocardiogram (EGG) changes suggestive of myocardial damage after starting olanzapine and lithium. An adverse medication effect was not considered at the time of the patient's admission. The time course of onset of weakness was coincident with administration of olanzapine. ECG abnormalities are a known manifestation of lithium therapy DISCUSSION: This is a case description of olanzapine-induced rhabdomyolysis. Although other antipsychotic agents have been reported to cause rhabdomyolysis, an adverse drug reaction was not initially part of this patient's differential diagnosis. The patient had begun reporting rnyalgias six days after starting olanzapine. Fourteen days later, these symptoms forced him to bed rest; lithium was added for behavior misinterpreted as disobedience and oppositional disorder. Only when medications were considered as cause of the weakness and EGG changes, was the true nature of the patient's illness discovered.
CONCLUSIONS: Olanzapine, like other neuroleptic agents, can cause rhabdomyolysis. Lithium can cause multiple EGG changes that can be misinterpreted as myocardial damage. Medication effects and adverse effects must always be considered in any disease complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573848     DOI: 10.1345/aph.10370

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

Review 1.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Serum creatine kinase elevation as a possible complication of therapy with olanzapine.

Authors:  Evgeniy Perlov; Ludger Tebartz van Elst; Martin Czygan; Emanuel Bubl; Dieter Ebert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

3.  Does Myocardial Necrosis Occur in Rhabdomyolysis?

Authors:  Gabriel M Aisenberg; Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2016-06-01

4.  Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.

Authors:  Cengiz Tuglu; Esin Erdogan; Ercan Abay
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

5.  Acute camptocormia induced by olanzapine: a case report.

Authors:  Florence Robert; Martial Koenig; Aurélie Robert; Stéphane Boyer; Pascal Cathébras; Jean-Philippe Camdessanché
Journal:  J Med Case Rep       Date:  2010-06-25

Review 6.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

7.  Postoperative creatine kinase elevation following hip arthroscopy and associated risk factors.

Authors:  Hisahiro Tonotsuka; Hajime Sugiyama; Daisuke Tanaka; Tatsuto Ito; Ayano Amagami; Keishi Marumo
Journal:  Acta Orthop Traumatol Turc       Date:  2019-09-16       Impact factor: 1.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.